이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

젊은 심장 연구

2026년 11월 5일 업데이트: Northwell Health

관상 동맥 심장 질환이 있는 젊은 환자 시험 - 위험 요소 평가 및 위험 감소 프로그램의 영향

The purpose of our project is to better understand the characteristics of the young patients with coronary artery disease presenting for cardiac catheterization at our institution and to put forth a program to optimize their risk factors with a focus on gender differences. We will assess traditional and non-traditional risk factors, as well as genetics and environment. These characteristics will be compared by gender to determine unique factors related to women that could subsequently be targeted. The program will begin with universal education about the process of atherosclerosis, risk factors contributing to the disease and specific risk factor goals for each patient for the 6 month program. The patients will then be part of a bimonthly 6 month cardiovascular risk reduction program that will offer both a nutritional program with teaching kitchen component, and exercise instruction lead by an exercise physiologist. Psychological support will be provided to address stress that impairs quality of life, depression or anxiety to fully optimize the lifestyle component. These sessions will be done virtually in order to comply with social distancing until in person sessions can resume.

The investigational endpoints of this program will include a variety of cardiovascular disease (CVD) risk factors, biomarkers, lifestyle behaviors, quality of life and guideline-based medical regimen. At the end of this phase, we aim to both better understand differences in risk factors and the interventions with the biggest impact in terms of risk factor optimization in men vs. women.

연구 개요

상세 설명

After enrollment, participants will meet with researchers where baseline characteristics will be obtained including biometrics such as weight, height, blood pressure, abdominal circumference, etc., as well as a questionnaire that will include validated screening tools for the screening for depression, anxiety, and stress, which are considered non-traditional risk factors for heart disease. The questionnaire will also include other aspects of the participant's lifestyle that could help better understand their risk for heart disease. This questionnaire will be available to be filled out on paper, via email which will be linked with REDCap, and in a tablet provided by our team with the data also being uploaded directly to REDCap.

Blood will also be collected by venipuncture (approximately 12milliliters, 6-8mL for standard of care labs, and 3-4mL for research labs) to assess inflammatory markers, lipids and glucose levels. If based on this initial screening, participants are thought to be at high risk for genetic disease, which likely predisposed them to develop heart disease, they will be offered genetic testing as part of their routine clinical care outside of this research, and an additional consent form will then be provided. We are planning to only recommend genetic testing as per clinical care in those for whom it is recommended by clinical guidelines. When a patient is deemed eligible from a clinical standpoint, they will be referred to our cardio ge-nomics team and be consented as per their clinical protocols and samples, either saliva or blood acquired by venipuncture (about 5ml), will be obtained. Source of sample will be determined by cardio genomics team and this will also fall under their standard of care. If the patient is being enrolled in the outpatient setting and has lab work within the past month, assuming no changes have been made to lipid lowering therapies during that time, we will only need to draw 3-4mL for research labs and possibly one additional tube for Lipoprotein(a), as it is not commonly included in basic lab work.

During their initial consultation while in the hospital, their individual risk will be assessed, and the patient will receive counseling on how to further improve said risk. These goals will be reinforced and measures to ensure those goals are met will be implemented when the patient comes to clinic within 2 weeks from their cardiac catheterization. During that visit, they will also be educated on the process of heart disease. Frequency of follow up in clinic will be determined on an individual basis based on individual risk factors, however, all patients are expected to be seen for a minimum of 3 times during those 6 months.

Soon after seeing us for that initial visit in clinic, the group risk reduction program will begin and will last for 6 months with 2 sessions per month (every other week), out of which participants will be required to attend at least 6 for maximum benefit. The sessions will include an exercise and nutrition program.

The nutrition program will be given by a Registered Dietitian Nutritionist and it will consist of a 60min session that will include about 10-15min education, 30min for a cooking demonstration where participants will be able to participate in the process of making heart healthy foods, and 10-15min for questions and answers. Food allergies will be reviewed prior to initiation of each session.

The exercise portion of the program will be led by a RRCA Level 1 Certified Coach from Achilles International, and the exercise will be low level exercise, at a level lower than even cardiac rehabilitation, which is usually recommended for patients after cardiac procedures. Regardless, the patient's cardiologist will indicate in writ-ing that it is safe to proceed with these sessions, which will be a 60min session provided by an exercise specialist.

Both nutrition and exercise sessions will occur between 5:30-6:30pm or 6pm-7pm at the Friedman Institute for Diabetes, and if the weather allows, some of the exer-cise sessions will be at Central Park. If needed, participants can also see a psy-chologist. Once the risk reduction program has ended, within a month we will re-evaluate the participants, repeat the initial questionnaire (excluding the demo-graphic data, past medical history and family history sections) and repeat blood work, with the exception of referral for genetic testing.

The registered dietitian and exercise coach are not considered investigators on this study as they will be performing their routine job function and will not be giving any new or different information to the participants of this study than what they would give to any other person joining them who are not part of this study. Addi-tionally, they will not be collecting any data either.

Results will be analyzed by gender with the intention to assess if some characteristics are unique to women compared to men, and the impact of the program on risk factors will also be assessed. Participants will also be called by one of the researchers about 1 month after the program has finished to assess if any changes in their lifestyle have persisted after the program, and once a year to follow up on cardiovascular events for 5yrs.

Addendum:

The Young Heart Study was designed to help subjects identify, educate, and reduce their risk of cardiovascular disease. The original structure of the study was to hold in-person sessions geared towards mental health, nutrition, and exercise. The widespread impact of COVID-19 forced the research team to pivot from the previ-ous model and include innovative virtual supplemental content.

The Young Heart Study has developed 3 instructional videos in the areas of mental health, nutrition, and exercise. These videos will be used in addition to physically distanced in-person events in accordance with CDC recommendations. The virtual content will not replace the original in-person events and is to be used in addition to the original study procedures.

The revised protocol is for ALL subjects to watch the video content and answer a short experiential survey (included on separate document). This survey will help the research team gauge impact of the videos and determine use case for the remain-der of the study.

The post-study survey provided after the 6 month period will be used to gauge perceived improvement by participant, improve relevant data collection, and add additional qualitative information to study team.

연구 유형

중재적

등록 (실제)

60

단계

  • 해당 없음

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 장소

    • New York
      • New York, New York, 미국, 10075
        • Lenox Hill Hospital

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 (성인)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion Criteria:

  • Patient with atherosclerotic cardiovascular disease

Exclusion Criteria:

  • Age 60 years or older
  • Physical limitation that will prevent them from being part of the exercise part of the study
  • Given that all the sessions will be given in English, participants not fluent in English will be excluded

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 다른
  • 할당: 해당 없음
  • 중재 모델: 단일 그룹 할당
  • 마스킹: 없음(오픈 라벨)

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: Risk Reduction Program

All participants will receive education about the process of atherosclerosis, risk factors contributing to the disease and specific risk factor goals for each patient for the 6 month program. The patients will then be part of a bimonthly 6 month cardiovascular risk reduction program that will offer both a nutritional program with teaching kitchen component, and exercise instruction lead by an exercise physiologist. Psychological support will be provided to address stress that impairs quality of life, depression or anxiety to fully optimize the lifestyle component.

Education, exercise, teaching kitchen and nutrition, and psychological support

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Change in Cardiovascular (CV) Risk Factor - Cholesterol levels
기간: 6 months

Will assess changes pre and post intervention in Low Density Lipoprotein Cholesterol level (measured in mg/dL)

6 months
Change in CV Risk Factor - Blood pressure
기간: 6 months

Will assess changes pre and post intervention in blood pressure (mmHg)

6 months
Change in CV Risk Factor - Glucometabolic state (A1C)
기간: 6 months

Will assess changes pre and post intervention in glycemic control measured by the hemoglobin A1C (%)

6 months
Change in CV Risk Factor - Smoking Status
기간: 6 months

Will assess changes pre and post intervention in smoking status (including quantity of cigarettes)

6 months
Change in CV Risk Factor - Physical activity/inactivity
기간: 6 months

Will assess changes pre and post intervention in physical activity which will be done through a questionnaire where participants will report the frequency and intensity of exercise

6 months
Change in CV Risk Factor - Overweight/Obesity
기간: 6 months

Will assess changes in weight by weighing patients on initial visit and again at follow-up. This value will be used in combination with patient's height to evaluate changes in body mass index.

6 months
Change in CV Risk Factors - Diet
기간: 6 months

Will assess changes pre and post intervention in diet which will be done via a food intake questionnaire

6 months
Change in CV Risk Factors - TMAO levels
기간: 6 months

Will assess changes pre and post intervention in trimethylamine N-oxide (TMAO) levels (microM)

6 months
Change in CV Risk Factors - hs-CRP levels
기간: 6 months

Will assess changes pre and post intervention in high sensitive C-reactive protein (hs-CRP) measured in mg/L

6 months
Change in Quality of Life Score
기간: 6 months

Surveys of Quality of Life and emotional well-being will be given at baseline and again at the end of the program

6 months

2차 결과 측정

결과 측정
측정값 설명
기간
Number of Cardiovascular events
기간: 5 years

Cardiovascular events assessed by a yearly phone call to the patient for up to 5 yrs

5 years

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

수사관

  • 수석 연구원: Eugenia Gianos, MD, Northwell Health

간행물 및 유용한 링크

연구에 대한 정보 입력을 담당하는 사람이 자발적으로 이러한 간행물을 제공합니다. 이것은 연구와 관련된 모든 것에 관한 것일 수 있습니다.

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2020년 5월 27일

기본 완료 (실제)

2022년 3월 28일

연구 완료 (실제)

2025년 2월 26일

연구 등록 날짜

최초 제출

2020년 2월 20일

QC 기준을 충족하는 최초 제출

2020년 7월 4일

처음 게시됨 (실제)

2020년 7월 8일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 11월 10일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 11월 5일

마지막으로 확인됨

2026년 11월 1일

추가 정보

이 연구와 관련된 용어

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

아니요

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다